Cortisol Modulation by Ayahuasca in Patients With Treatment Resistant Depression and Healthy Controls
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Major depression is a highly prevalent mood disorder, affecting about 350 million people, and around 30% of the patients are resistant to currently available antidepressant medications. Recent evidence from a randomized controlled trial (RCT) supports the rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression. The aim of this study was to explore the effect of ayahuasca on plasma cortisol and awakening salivary cortisol response, in the same group of treatment-resistant patients (MD) and in healthy volunteers (C). Subjects received a single dose of ayahuasca or placebo (dosing session), and both plasma and awakening salivary cortisol response were measured at baseline (before dosing session) and 48 h after the dosing session. Baseline assessment (D0) showed blunted awakening salivary cortisol response and hypocortisolemia in patients, with respect to healthy controls. Salivary cortisol was also measured during dosing session, and we observed higher increases for both C and MD that ingested ayahuasca than placebo. After 48 h from the dosing session with ayahuasca, patients' awakening salivary cortisol response is similar to the ones detected in controls. No significant changes in plasma cortisol levels were observed 48 h after the sessions. Therefore, these findings point to new evidence on the modulation of salivary cortisol levels as a result of an ayahuasca session, both in healthy and depressive volunteers. Considering that cortisol acts in regulation of distinct physiological pathways, emotional and cognitive processes, it is assumed to be critically involved to the etiology of depression and its regulation seems to be important for the treatment and remission of major depression, ayahuasca use as antidepressant should be further investigated. Moreover, this study highlights the importance of psychedelics in the treatment of human mental disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sapolsky, R. M., Romero, L. M., & Munck, A. U. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.1.0389 · Cited by 7,541 · cited 1×
“This finding probably corroborates with the improvement of several physiological systems, emotional and cognitive aspects that are regulated by cortisol (83, 84).”
Sapolsky, R. M. (2000) · Endocrine Reviews · doi:10.1210/er.21.1.55 · Cited by 7,533
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Gold, P. W., & Chrousos, G. P. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001032 · Cited by 1,274
The cortisol awakening response (CAR): Facts and future directions
Fries, E., Dettenborn, L., & Kirschbaum, C. (2009) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2008.03.014 · Cited by 1,188
Post-Traumatic Stress Disorder
Yehuda, R. (2002) · New England Journal of Medicine · doi:10.1056/nejmra012941 · Cited by 1,134
Corticosteroid insufficiency in acutely ill patients
Cooper, M. S., & Stewart, P. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020529 · Cited by 1,033
Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osório, F. L., Sanches, R., dos Santos, R. G., et al. (2019) · Psychological Medicine · doi:10.1017/s0033291718001356 · Cited by 852
Self-citationPenninx, B. W., Milaneschi, Y., Lamers, F., & Vogelzangs, N. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-129 · Cited by 839
The neurobiology of depression: An integrated view
Dean, J., & Keshavan, M. (2017) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2017.01.025 · Cited by 765
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Vollenweider, F. X., & Kometer, M. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2884 · Cited by 723
Lamers, F., Vogelzangs, N., Merikangas, K. R., de Jonge, P., Beekman, A. T. F., & Penninx, B. W. J. H. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.144 · Cited by 691
The Hallucinogen N,N -Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor Regulator
Fontanilla, D., Johannessen, M., Hajipour, A. R., Cozzi, N. V., Jackson, M. B., & Ruoho, A. E. (2009) · Science · doi:10.1126/science.1166127 · Cited by 535
Sanches, R. F., de Lima Osório, F., dos Santos, R. G., Macedo, L. R. H., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000436 · Cited by 466
Self-citationThe pharmacology of psilocybin
Passie, T., Seifert, J., Schneider, U., & Emrich, H. M. (2002) · Addiction Biology · doi:10.1080/1355621021000005937 · Cited by 465 · cited 1×
“Previous studies in healthy subjects have also reported increased cortisol levels during the acute effects of ayahuasca (72–74), N,N-DMT (75), psilocybin (76, 77), and Lysergic Acid Diethylamide (LSD) (78).”
Hasler, F., Grimberg, U., Benz, M. A., Huber, T., & Vollenweider, F. X. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1640-6 · Cited by 451 · cited 1×
“Previous studies in healthy subjects have also reported increased cortisol levels during the acute effects of ayahuasca (72–74), N,N-DMT (75), psilocybin (76, 77), and Lysergic Acid Diethylamide (LSD) (78).”
McKenna, D. J., Towers, G. H. N., & Abbott, F. (1984) · Journal of Ethnopharmacology · doi:10.1016/0378-8741(84)90003-5 · Cited by 398
Diagnosis of Adrenal Insufficiency in Severe Sepsis and Septic Shock
Annane, D., Maxime, V., Ibrahim, F., Alvarez, J. C., Abe, E., & Boudou, P. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200509-1369oc · Cited by 327
Prospective prediction of major depressive disorder from cortisol awakening responses in adolescence
Adam, E. K., Doane, L. D., Zinbarg, R. E., Mineka, S., Craske, M. G., & Griffith, J. W. (2010) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2009.12.007 · Cited by 315
Bouso, J. C., González, D., Fondevila, S., Cutchet, M., Fernández, X., Ribeiro Barbosa, P. C., Alcázar-Córcoles, M. Á., Araújo, W. S., Barbanoj, M. J., Fábregas, J. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042421 · Cited by 313
Cortisol and depression: three questions for psychiatry
Herbert, J. (2013) · Psychological Medicine · doi:10.1017/s0033291712000955 · Cited by 301
Rapid Reversal of Psychotic Depression Using Mifepristone
Belanoff, J. K., Flores, B. H., Kalezhan, M., Sund, B., & Schatzberg, A. F. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200110000-00009 · Cited by 282
The therapeutic potentials of Ayahuasca: possible effects against various diseases of civilization
Frecska, E., Bokor, P., & Winkelman, M. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00035 · Cited by 242
Assessment of addiction severity among ritual users of ayahuasca.
Fábregas, J. M., González, D., Fondevila, S., Cutchet, M., Fernández, X., Barbosa, P. C. R., Alcázar-Córcoles, M. Á., Barbanoj, M. J., Riba, J., & Bouso, J. C. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.03.024 · Cited by 227
Morning cortisol as a risk factor for subsequent major depressive disorder in adult women
Harris, T. O., Borsanyi, S., Messari, S., Stanford, K., Cleary, S. E., Shiers, H. M., Brown, G. W., & Herbert, J. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.177.6.505 · Cited by 220
Bouso, J. C., Palhano-Fontes, F., Rodríguez-Fornells, A., Ribeiro, S., Sanches, R., Crippa, J. A. S., Hallak, J. E. C., de Araujo, D. B., & Riba, J. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.008 · Cited by 218 · cited 1×
“Regular ayahuasca users in religious contexts have shown low level of psychopathologies (33–35), low scores on the state scales related to panic and hopelessness (36), as well as good performances in cognitive neuropsychological tests (37, 38).”
Self-citationEvaluation of the Integrity of the Hypothalamic-Pituitary-Adrenal Axis by Insulin Hypoglycemia Test1
Erturk, E., Jaffe, C. A., & Barkan, A. L. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.7.4980 · Cited by 204 · cited 1×
“Studies that evaluated the utility of basal morning serum cortisol measurements in the diagnosis of adrenal insufficiency showed that a threshold of 10 mcg/dL leads to 77% of specificity, and 62% sensitivity, defined by a subnormal serum cortisol response to insulin-induced hypoglycemia (68, 69).”
Clinical and Biological Effects of Mifepristone Treatment for Psychotic Depression
Flores, B. H., Kenna, H., Keller, J., Solvason, H. B., & Schatzberg, A. F. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300884 · Cited by 203 · cited 1×
“Although there is great evidence that normalization of HPA axis function is essential for the successful treatment of depressive patients (89, 94, 95) differently of our hypothesis, herein changes in cortisol levels induced by ayahuasca were not correlated with improvement in depressive symptoms observed from D1 to D7…”
Neuroendocrinological mechanisms of actions of antidepressant drugs
Schüle, C. (2007) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2006.01516.x · Cited by 167 · cited 2×
“Noradrenaline or serotonin (5HT) reuptake-inhibiting antidepressants, such as reboxetine and citalopram, acutely stimulate cortisol secretion in healthy volunteers, probably due the elevation in 5HT levels (79, 80).”
Pharmacology of ayahuasca administered in two repeated doses
dos Santos, R. G., Grasa, E., Valle, M., Ballester, M. R., Bouso, J. C., Nomdedéu, J. F., Homs, R., Barbanoj, M. J., & Riba, J. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2434-x · Cited by 141
Biomarkers of stress in behavioural medicine
Nater, U. M., Skoluda, N., & Strahler, J. (2013) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328363b4ed · Cited by 125
Salivary cortisol levels and the 2-year course of depressive and anxiety disorders
Vreeburg, S. A., Hoogendijk, W. J. G., DeRijk, R. H., van Dyck, R., Smit, J. H., Zitman, F. G., & Penninx, B. W. J. H. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.12.017 · Cited by 121 · cited 2×
“Major depression has been traditionally associated with hypercortisolism, but an increasing number of studies have found evidence of hypocortisolism in depression (8, 46, 47).”
Health status of ayahuasca users
Barbosa, P. C. R., Mizumoto, S., Bogenschutz, M. P., & Strassman, R. J. (2012) · Drug Testing and Analysis · doi:10.1002/dta.1383 · Cited by 112
Hinkelmann, K., Moritz, S., Botzenhardt, J., Muhtz, C., Wiedemann, K., Kellner, M., & Otte, C. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2011.08.012 · Cited by 103
Fortunato, J. J., Réus, G. Z., Kirsch, T. R., Stringari, R. B., Fries, G. R., Kapczinski, F., Hallak, J. E., Zuardi, A. W., Crippa, J. A., & Quevedo, J. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0451-2 · Cited by 98
Cited by
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Almeida, R. N. D., Galvão, A. C. D. M., da Silva, F. S., Silva, E. A. D. S., Palhano-Fontes, F., Maia-de-Oliveira, J. P., de Araújo, L.-S. B., Lobão-Soares, B., & Galvão-Coelho, N. L. (2019) · Frontiers in Psychology · doi:10.3389/fpsyg.2019.01234 · Cited by 177
Self-citationGalvão-Coelho, N. L., Marx, W., Gonzalez, M., Sinclair, J., de Manincor, M., Perkins, D., & Sarris, J. (2021) · Psychopharmacology · doi:10.1007/s00213-020-05719-1 · Cited by 137
Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca
Galvão-Coelho, N. L., de Menezes Galvão, A. C., de Almeida, R. N., Palhano-Fontes, F., Campos Braga, I., Lobão Soares, B., Maia-de-Oliveira, J. P., Perkins, D., Sarris, J., & de Araujo, D. B. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120936486 · Cited by 128
“However, this correlation at baseline was not observed in the control group, probably because they presented eucortisolemia (Galvão et al., 2018).”
BackgroundMethodInfluentialSelf-citationdos Santos, R. G., & Hallak, J. E. C. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.12.001 · Cited by 111
Metadata
- Authors
- Galvão, A. C. D. M., de Almeida, R. N., Silva, E. A. D. S., Freire, F. A. M., Palhano-Fontes, F., Onias, H., Arcoverde, E., Maia-de-Oliveira, J. P., de Araújo, D. B., Lobão-Soares, B., & Galvão-Coelho, N. L.
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2018-05-08
- Volume
- 9
- Pages
- 185-185
- ISSN
- 1664-0640 (ISSN-L)
- OpenAlex
- W2801130428
- Cited by
- 108
- References
- 38
- FWCI
- 13.27
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.